The National Cancer Institute has launched a three to four year broad-based study of exceptional responders--patients who have had particularly good outcomes on cancer therapies as compared to their peers. The initiative was first considered a few years ago when it started to become easier to determine the molecular basis of why a particular patient's cancer responds to a molecularly targeted drug, but it is only being undertaken now.
A Purdue University team has created a new chip that promises to help test how cancer-killing nanoparticles react in a tumor environment. Because different nanoparticles perform vastly different functions in drug delivery, it's important to determine early on what kind of effect they will have on a tumor and what it would take to improve their outcome.
Combining chemotherapy and radiotherapy would be ideal for cancer treatment, but administering both at the same time can lead to unacceptable and often deadly levels of toxicity. Now researchers have developed liposomes that contain a chemotherapy drug activated by radiotherapy, offering both cancer-killing power and a targeted approach in a more controlled manner.
ReWalk Robotics, which offers the first robotic exoskeleton for spinal cord injury patients to be cleared by FDA, raised $36 million in an IPO. It didn't wow investors too much--pricing below the anticipated range. Meanwhile, another medical device company stepped into the IPO queue; proton radiation therapy company Mevion Medical Systems filed to raise up to $69 million.
A bioengineering professor says he has developed nanoparticles that can carry cancer-fighting insect toxins directly to tumors, sparing the rest of the body from nasty side effects, including damage to the heart, bleeding underneath the skin and unwanted clotting.
Ophthalmology company Oraya Therapeutics will collaborate with researchers from Boston's Dana-Farber Cancer Institute to study applications of its novel radiation therapy against cancer when used in conjunction with gold nanoparticles.
PatientsLikeMe is continuing to expand its business into new areas. Having struck its first broad R&D collaboration with a biopharma earlier this year, the online patient network has now given Actelion access to its community to create a new health outcome measure for a rare cancer.
Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.
The technology going into the device, called Rapid Evaporative Ionization Mass Spectrometry, by the Waters Corporation, is a move that one of the developers hopes will give the project new momentum.
Researchers have developed a computational cancer model to predict how a drug will perform in humans, VentureBeat reports.